AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06404112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep.
Study NCT06404112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melantonin Placebo
Description: Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
Study NCT06404112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melantonin Placebo
Description: Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime.
Study NCT06404112 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored lighting (TL) Active
Description: TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
Study NCT06404112 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored lighting (TL) Placebo
Description: TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
Study NCT06404112 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tailored lighting (TL) Placebo
Description: TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants.
Study NCT04978896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-guided program on stress coping
Description: This is an 8-day program that provides psychoeducation on the negative effects of stress and effective stress-management skills to combat stress. Guided by principles of CBT, the program targets the thoughts and behaviours of participants and equips them with skills to alter negative cognitions pertaining to stress. Participants are engaging with a series of exercises involving reflection and mindfulness where they are required to spot and write down their stressors, the negative thoughts associated with the stressors, as well as positive affirmations. Participants will also be taught breathing exercises and are encouraged to practice them during 2 check-ins.
Study NCT04978896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided program on cooperation
Description: The 8-day program on cooperation aims to provide psychoeducation for participants to understand and improve collaboration and interpersonal relationships. Short quizzes and practice exercises on feedback-giving will be included. The time and duration of the cooperation SGA is matched to the stress-coping SGA to ensure that participants spend a similar amount of time and effort across both the intervention and active-control conditions.
Study NCT05440877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR materials
Description: In the lecture room for the intervention group, participants in the intervention group will be given QR codes for viewing these online videos and VR cardboards, a web including photo hunt sections that allow viewers to find cues for smoking cessation treatment. They are asked to view these videos and photos with their own mobile phones.
Study NCT05440877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tutorial guide
Description: A tutorial guide including description of the smokers' cases
Study NCT04213300 — intervention group
Intervention type: OTHER
Intervention: Low carbohydrate diet
Description: Study duration: 13 weeks (run in phase = 1 week; low carbohydrate diet phase = 12 weeks).~Each participant will be provided with an individualised meal plans to meet their energy needs as per the Schofield formula and a macronutrient distribution of 20% for carbohydrate, 25% for protein and 55% for fat.~Participants will self-report quality of life using a validated diabetes specific quality of life questionnaire for Australian adults and HbA1c (pre and post intervention phase of 13 weeks duration) .
Study NCT05533346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: with WISE (Walking Instruction based on Self-Efficacy)
Description: Will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring. Only the experimental group will be additionally given the interventional treatment of the WISE program: walk three times a week for at least 30 minutes each time, with a pace between 100-130 steps/min, and then increase the number or time weekly according to your personal ability, and remind you if the monitoring heart rate is higher than 170 times/min or the blood oxygen concentration is lower than 95%, and if the body feels any discomfort, it is necessary to stop taking a rest, and an educational strategy for improving self-efficacy of walking for 12 weeks is also provided.
Study NCT05533346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: without WISE (Walking Instruction based on Self-Efficacy)
Description: The procedure of the control group was the same as that of the experimental group, both of which will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring.
Study NCT06345248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-TAP
Description: regional block team under ultrasound guidance
Study NCT06345248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPTAP
Description: performed TAP block under direct visualization with the laparoscope
Study NCT04697966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness (Headspace) App
Description: The Headspace app consists of guided mindfulness meditations and is available for both Apple iOS and Android devices. For the proposed study, participants will be instructed to complete the app's most popular introductory program which consists of three levels (Basics 1-3), with each level comprising 10 sessions (30 in total) over 30 days. The program is intended to introduce the key principles and techniques of mindfulness (including focused meditation on the breath, body scanning, and noting), and strategies for applying mindfulness to daily life.
Study NCT04697966 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Condition (Recharge condition delivered in Headspace app)
Description: The majority of prior research on mindfulness interventions has relied on single-arm designs or wait-list controls conditions, rather than active control conditions. Accordingly, we will include a structurally-equivalent active control condition, delivered via the same Headspace app. Specifically, the control condition will consist of 30 guided Recharge sessions led by Andy Puddicombe (i.e., structurally equivalent to the Mindfulness app). The sessions are the same length as the interventions (Basics) sessions and also delivered via the Headspace app, thus closely matching the mindfulness intervention across key attributes. Specifically, user flow through the app is identical in both the mindfulness and control conditions, differing only in session content. The Recharge sessions include guide reflections, guided positive imagery, problem solving and daily planning. The chosen excerpts exclude any content which feature guided mindfulness exercises.
Study NCT05467423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron
Description: 4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.
Study NCT05467423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron
Description: 4 weeks of daily oral iron therapy. The subjects administer the therapy themselves.
Study NCT05681650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HypoSti.CAR-HER2 T cells
Description: Dose escalation: dose -1 (1×10\^6 cells/kg) ,dose 1 (3×10\^6 cells/kg) , dose 2 (6×10\^6 cells/kg), dose 3 (1×10\^7 cells/kg), dose 4 (1.5×10\^7 cells/kg). Dose expansion: RP2D
Study NCT05681650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered intravenously at dose of 100-200mg/m2 on day -5
Study NCT05681650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously at a total dose of 15-30mg/kg on day -3 and day-2
Study NCT05681650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously at dose of 30mg/m2/d on day -3 and day -2 only in the first infusion of HypoSti.CAR-HER2 T cells
Study NCT05821985 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: The study group
Description: The patients within the study group will receive intraarticular TMJ and masseteric Trigger point injection of a solution that contains (0.75 ml. 12.5% Dextrose solution, 0.75 ml. Saline solution, and 1.5 ml. Lidocaine). Each patient will receive four injections at two-week intervals, aided by a 25 gauge needle connected to a 3 ml. plastic syringe.
Study NCT05821985 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: The Control group
Description: The Control group:~Patients in the control group will receive intraarticular TMJ and masseteric Trigger point dry needle insertion without injecting any solution. Each patient will receive four dry needle insertions at two-week intervals, aided by a 25-gauge and 3.8 cm length needle.~i.e., All the patients will be subjected to intraarticular needle insertion. However, only the patients within the study group will be injected with the Dextrose Prolotherapy solution.
Study NCT03909893 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiation Therapy
Description: Cone-beam CT images as well as MRI scans will be used to make any changes to the radiation treatment plan, part of the way through the treatment. Adaptation of treatment plans may allow smaller target volumes to be treated with higher doses, while minimizing the side effects to surrounding organs.
Study NCT05401162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion with haematopoietic stem cells
Description: Transfusion of autologous blood containing haematopoietic stem cells for haematopoietic reconstruction after chemotherapy.Blood tests were performed weekly, if the patient's neutrophils were less than 1.0 × 109 / L during chemotherapy, G-CSF was given as a remedial treatment. If fever occurs, antibiotics were given promptly.Monitor peripheral blood after transfusion. If peripheral blood leukocyte count does not reach 1.0 x 109/L, administer G-CSF 150 μg subcutaneously daily until peripheral blood leukocyte count reaches 1.0 x 109/L.Patients were tested monthly for peripheral blood cells for 6 months after the end of treatment.
Study NCT06523335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular coordination-guided rehabilitative training
Description: During training exercise, post-stroke participants will be asked to match the targets on the screen. The experimental group will match them by activating a specific set of muscle. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
Study NCT06523335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Force strengthening-guided rehabilitative training
Description: During training exercise, post-stroke participants will be asked to match the targets on the screen. The active comparator group will match them by generating isometric force in a desired target direction. During assessment trials, a physical therapist or occupational therapist will rate the functional level of arm impairment using FMA and ARAT.
Study NCT05730725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986322
Description: Specified dose on specified days
Study NCT05730725 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT05802004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic Stimulation (STIM)
Description: During the in-lab overnight, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
Study NCT05802004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Acoustic Stimulation (SHAM)
Description: During the in-lab overnight, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
Study NCT05802004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily acoustic stimulation (STIM2)
Description: During the \~2 weeks at home, a headband device will be used to administer acoustic stimulation. Tones will be played during slow-wave sleep to enhance underlying slow-wave activity (0.5 - 4 Hz delta spectral power).
Study NCT05802004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No daily acoustic stimulation (SHAM2)
Description: During the \~2 weeks at home, the participant will wear a headband device, but the device will not administer acoustic stimulation. The device will be on and will still monitor sleep, but will not play tones.
Study NCT05454774 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Single dose intravenous injection of BBM 002
Description: Single dose intravenous infusion of BBM 002, an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII (hFVIII) transgene in liver. The dose of BBM 002 will be 1×10\^13 vg/ kg
Study NCT05412147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RECO-18
Description: 4 pills daily, oral
Study NCT05412147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-vitamins
Description: one tablet daily, oral
Study NCT05427981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belbuca Buccal Product
Description: Buprenorphine Buccal Films
Study NCT05427981 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Buccal Films
Study NCT06005415 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wire-cut cookie
Description: Investigation of the impact of wheat particle size on the postprandial glycemic response, gastric emptying and oral processing behavior after consumption of wire-cut cookies.
Study NCT04761601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCT-01-097
Description: Orally available kinase inhibitor
Study NCT04761601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine injection for intravenous use.
Study NCT04761601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel protein-bound particles for injectable suspension (albumin-bound).
Study NCT04975698 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HST-NEETs
Description: HST-NEETs are manufactured from an autologous peripheral blood or MNCs via apheresis collection and will be administered as a single intravenous (IV) infusion of 2x10\^7/m\^2 cells between 3 Days and 7 Days post-ASCT.
Study NCT04975698 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bone Marrow Transplant
Description: Day 0 is the day of bone marrow transplantation.
Study NCT05767008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen -R43
Description: Long wear metal oxide particles
Study NCT05241262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 1800, 3600 or 5400 mg NAC per day (divided into 3 daily doses) depending on dose toxicity plan
Study NCT04144153 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Opioid Free Total Intravenous Anesthesia
Description: Total intravenous anesthesia with propofol and dexmedetomidine hydrochloride and ketamine hydrochloride
Study NCT04144153 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Total Intravenous anesthesia with opioid
Description: Total Intravenous anesthesia with opioid
Study NCT06304961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozorakimab
Description: Tozorakimab will be administered as a single SC dose on Day 1.
Study NCT05208476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative medicine
Description: A set of hands-on techniques used by osteopathic physicians to help diagnose, treat and prevent illness or disease.
Study NCT05284773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caretaker MUAC screening - training by health workers
Description: Study personnel will train caregivers to conduct weekly AM screening using the color-coded MUAC tape. AM screening will involve identifying the midpoint of the child's right arm, wrapping the tape around the mid-point, inserting one end of the tape through the slit at the other end, pulling the tape secure, and reading the measurement based on the color bands. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be provided with a referral slip to do so. Caregivers will be informed of the signs, symptoms, and consequences of malnutrition as well as the available nutritional programs. Study personnel will conduct monthly supervision visits including brief refresher trainings. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
Study NCT05284773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caretaker MUAC screening - training by caregivers
Description: Study personnel will train a group of caregivers to perform AM training of all caregivers living in their communities. they will instruct caregivers to conduct weekly AM screening. Training will include the same information as the communities receiving training by Health workers: MUAC training and how to interpret MUAC as well as key concepts of malnutrition. Caregivers will be trained to refer children with yellow or red readings to the nearest CSPS and will be. In all study communities, standard of care screening for AM will continue. This includes biannual community-based screening by community health workers as well as weekly malnutrition days led by the CSPS.
Study NCT05907759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC
Description: Daratumumab SC (daratumumab and hyaluronidase) is administered subcutaneously (SC) as 1800 mg/30,000 units weekly for a total of 8 weeks (8 doses) followed by every 2 weeks for a total of 16 weeks (8 doses) followed by every 4 weeks for up to 96 weeks (24 doses)
Study NCT06510933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heel cups in different BMI index and its correlation to physical activity in children
Description: Procedure: Group with muscle retraction will use a 5 millimeter heel cups in 3 and 6 months
Study NCT06422377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soticlestat
Description: Soticlestat tablets or mini-tablets
Study NCT06472661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echopulse or Echopulse HD
Description: The Echopulse/Echopulse HD device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate (heat and destroy) tissue. A series of sound waves will be focused on the tumor using the Echopulse or the Echopulse HD device to cover the planned target area. The targeted area is 33% of the tumor, up to 3.5 cubic centimeters. An ultrasound will be used to guide the beam of the FUSA treatment to the targeted site. FUSA will be applied to up to two tumors in the session. Participants are sedated during the FUSA treatment.
Study NCT06472661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyICLC
Description: PolyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine) is a drug that may help the body build an effective immune response to kill tumor cells. A single injection of .9 mg of polyICLC into one tumor will be given within 4 hours after the FUSA.
Study NCT05763017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relative Motion Splint
Description: Six weeks relative motion splint wear.
Study NCT05763017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metacarpophalangeal Joint Blocking Splint
Description: Six weeks metacarpophalangeal joint blocking splint wear.
Study NCT05846126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RehabCovid_Telematic
Description: A multimodal and digitally-based cognitive training, physical exercise, and mindfulness intervention delivered remotely.
Study NCT05846126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RehabCovid_ImmersiveVR
Description: A multimodal and digitally-based cognitive training, physical exercise and mindfulness intervention delivered face to face and through 360MK Virtual Reality technology
Study NCT05846126 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control_Condition
Description: Traditional paper or pdf format multimodal intervention that will combine cognitive, mediation and physical activities.
Study NCT05871541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCXH-105
Description: As IM injection
Study NCT05871541 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control (Shingrix)
Description: As IM injection
Study NCT05905094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural correction exercises
Description: Exercises to improve posture like shoulder shrugging, chin tuckin, neck isometrics